Ultragenyx Pharmaceutical (RARE) Other Working Capital Changes (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Other Working Capital Changes data on file, last reported at $9.0 million in Q1 2026.

• Other Working Capital Changes for Q1 2026 came in at $9.0 million, down 47.06% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.0 million (down 82.69% YoY), and the FY2025 annual result was $10.0 million, up 183.33% from the prior year.
• Other Working Capital Changes climbed to $9.0 million in Q1 2026 per RARE's latest filing, from $2.7 million in the prior quarter.
• Over five years, Other Working Capital Changes peaked at $17.0 million in Q1 2025 and troughed at -$12.7 million in Q3 2024.
• A 5-year average of -$694000.0 and a median of $165000.0 in 2025 frame the typical range for Other Working Capital Changes.
• The sharpest annual moves came in 2022 and 2024: Other Working Capital Changes soared 1062.45% in 2022, then tumbled 1362.62% in 2024.
• A 5-year view of Other Working Capital Changes shows it stood at -$3.2 million in 2022, then surged by 148.89% to $1.6 million in 2023, then slumped by 83.02% to $269000.0 in 2024, then jumped by 918.59% to $2.7 million in 2025, then surged by 228.47% to $9.0 million in 2026.
• Business Quant data shows RARE's Other Working Capital Changes at $9.0 million in Q1 2026, $2.7 million in Q4 2025, and -$9.9 million in Q3 2025.